Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Medical Information FSGS

FILSPARI (sparsentan) – Concomitant Medications Included in Clinical Trials

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Changes in Blood Pressure and Hypotensive Events

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Safety and Efficacy in Focal Segmental Glomerulosclerosis (FSGS)

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Use with Diuretics in IgA Nephropathy and FSGS

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – In Combination With Immunosuppressant Therapy in IgA Nephropathy

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Transitioning from ACEi/ARB Treatment to Sparsentan in Clinical Trials

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Dosing and Administration in Clinical Trials

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Safety in Clinical Trials

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – Management of Edema in Patients With IgA Nephropathy in the PROTECT Study

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Edema and Congestive Heart Failure

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Drug-Drug Interactions

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Pharmacokinetic Profile

Learn more
Posters

Sparsentan, the dual endothelin and angiotensin receptor antagonist (DEARA), improves kidney function and lifespan and protects against hearing loss in Alport mice with developed renal structural changes

Learn More